Navidea Biopharmaceuticals, Inc. (NAVB)
USD 0.0
(16.67%)
USD 0.0
(16.67%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 12.51 Million USD | 107.89% |
| 2021 | 6.02 Million USD | 5.41% |
| 2020 | 5.71 Million USD | 13.5% |
| 2019 | 5.03 Million USD | 9.13% |
| 2018 | 4.61 Million USD | -47.2% |
| 2017 | 8.73 Million USD | -89.1% |
| 2016 | 80.12 Million USD | 16.46% |
| 2015 | 68.8 Million USD | 64.9% |
| 2014 | 41.72 Million USD | -5.87% |
| 2013 | 44.32 Million USD | 231.34% |
| 2012 | 13.37 Million USD | 32.95% |
| 2011 | 10.06 Million USD | 49.49% |
| 2010 | 6.73 Million USD | -64.36% |
| 2009 | 18.88 Million USD | 95.82% |
| 2008 | 9.64 Million USD | -12.37% |
| 2007 | 11 Million USD | 32.11% |
| 2006 | 8.33 Million USD | 10.3% |
| 2005 | 7.55 Million USD | -17.91% |
| 2004 | 9.2 Million USD | 332.81% |
| 2003 | 2.12 Million USD | -31.85% |
| 2002 | 3.11 Million USD | -29.5% |
| 2001 | 4.42 Million USD | -3.95% |
| 2000 | 4.6 Million USD | -55.96% |
| 1999 | 10.46 Million USD | 45.94% |
| 1998 | 7.16 Million USD | -20.52% |
| 1997 | 9.01 Million USD | 4.92% |
| 1996 | 8.59 Million USD | 109.66% |
| 1995 | 4.1 Million USD | 0.0% |
| 1994 | 4.1 Million USD | 127.78% |
| 1993 | 1.8 Million USD | 200.0% |
| 1992 | 600 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q3 | 8.67 Million USD | -3.64% |
| 2023 Q1 | 11.91 Million USD | -4.79% |
| 2023 Q2 | 9 Million USD | -24.41% |
| 2022 Q3 | 10.92 Million USD | 62.0% |
| 2022 Q2 | 6.74 Million USD | 18.08% |
| 2022 Q1 | 5.71 Million USD | -5.12% |
| 2022 FY | 12.51 Million USD | 107.89% |
| 2022 Q4 | 12.51 Million USD | 14.55% |
| 2021 Q1 | 5.06 Million USD | -11.26% |
| 2021 Q2 | 4.84 Million USD | -4.4% |
| 2021 Q3 | 4.82 Million USD | -0.4% |
| 2021 Q4 | 6.02 Million USD | 24.75% |
| 2021 FY | 6.02 Million USD | 5.41% |
| 2020 Q1 | 5.56 Million USD | 10.66% |
| 2020 Q3 | 5.09 Million USD | -41.64% |
| 2020 FY | 5.71 Million USD | 13.5% |
| 2020 Q4 | 5.71 Million USD | 12.1% |
| 2020 Q2 | 8.72 Million USD | 56.77% |
| 2019 Q3 | 4.91 Million USD | -5.47% |
| 2019 Q1 | 4.86 Million USD | 5.51% |
| 2019 Q2 | 5.19 Million USD | 6.86% |
| 2019 FY | 5.03 Million USD | 9.13% |
| 2019 Q4 | 5.03 Million USD | 2.39% |
| 2018 Q4 | 4.61 Million USD | -35.05% |
| 2018 FY | 4.61 Million USD | -47.2% |
| 2018 Q1 | 13.37 Million USD | 53.13% |
| 2018 Q2 | 5.87 Million USD | -56.08% |
| 2018 Q3 | 7.09 Million USD | 20.86% |
| 2017 Q2 | 8.56 Million USD | -18.93% |
| 2017 Q1 | 10.56 Million USD | -86.82% |
| 2017 Q4 | 8.73 Million USD | 32.51% |
| 2017 Q3 | 6.59 Million USD | -23.02% |
| 2017 FY | 8.73 Million USD | -89.1% |
| 2016 Q2 | 72.58 Million USD | 4.53% |
| 2016 Q1 | 69.44 Million USD | 0.94% |
| 2016 Q4 | 80.12 Million USD | 6.89% |
| 2016 Q3 | 74.96 Million USD | 3.27% |
| 2016 FY | 80.12 Million USD | 16.46% |
| 2015 Q4 | 68.8 Million USD | -0.73% |
| 2015 Q1 | 46.28 Million USD | 10.92% |
| 2015 FY | 68.8 Million USD | 64.9% |
| 2015 Q2 | 66.81 Million USD | 44.37% |
| 2015 Q3 | 69.3 Million USD | 3.72% |
| 2014 Q1 | 47.24 Million USD | 6.59% |
| 2014 FY | 41.72 Million USD | -5.87% |
| 2014 Q2 | 47.42 Million USD | 0.37% |
| 2014 Q4 | 41.72 Million USD | -14.68% |
| 2014 Q3 | 48.9 Million USD | 3.12% |
| 2013 Q2 | 32.95 Million USD | 101.85% |
| 2013 Q3 | 41.07 Million USD | 24.65% |
| 2013 FY | 44.32 Million USD | 231.34% |
| 2013 Q4 | 44.32 Million USD | 7.92% |
| 2013 Q1 | 16.32 Million USD | 22.03% |
| 2012 Q3 | 10.85 Million USD | 7.61% |
| 2012 Q1 | 10.02 Million USD | -0.42% |
| 2012 Q4 | 13.37 Million USD | 23.26% |
| 2012 FY | 13.37 Million USD | 32.95% |
| 2012 Q2 | 10.08 Million USD | 0.65% |
| 2011 Q2 | 5.9 Million USD | 9.7% |
| 2011 Q4 | 10.06 Million USD | 105.59% |
| 2011 FY | 10.06 Million USD | 49.49% |
| 2011 Q1 | 5.38 Million USD | -19.96% |
| 2011 Q3 | 4.89 Million USD | -17.18% |
| 2010 Q1 | 20.3 Million USD | 7.5% |
| 2010 FY | 6.73 Million USD | -64.36% |
| 2010 Q4 | 6.73 Million USD | 14.63% |
| 2010 Q3 | 5.87 Million USD | 13.19% |
| 2010 Q2 | 5.18 Million USD | -74.45% |
| 2009 FY | 18.88 Million USD | 95.82% |
| 2009 Q1 | 24.13 Million USD | 150.19% |
| 2009 Q4 | 18.88 Million USD | -3.65% |
| 2009 Q3 | 19.6 Million USD | -47.5% |
| 2009 Q2 | 37.33 Million USD | 54.74% |
| 2008 Q1 | 8.2 Million USD | -25.41% |
| 2008 Q4 | 9.64 Million USD | 6.4% |
| 2008 Q2 | 8.56 Million USD | 4.3% |
| 2008 FY | 9.64 Million USD | -12.37% |
| 2008 Q3 | 9.06 Million USD | 5.86% |
| 2007 Q4 | 11 Million USD | 35.22% |
| 2007 FY | 11 Million USD | 32.11% |
| 2007 Q1 | 8.19 Million USD | -1.64% |
| 2007 Q2 | 8.06 Million USD | -1.57% |
| 2007 Q3 | 8.13 Million USD | 0.91% |
| 2006 Q2 | 7.21 Million USD | -1.79% |
| 2006 Q1 | 7.34 Million USD | -2.73% |
| 2006 FY | 8.33 Million USD | 10.3% |
| 2006 Q4 | 8.33 Million USD | 11.1% |
| 2006 Q3 | 7.49 Million USD | 3.93% |
| 2005 Q2 | 7.1 Million USD | 4.52% |
| 2005 Q4 | 7.55 Million USD | 8.38% |
| 2005 FY | 7.55 Million USD | -17.91% |
| 2005 Q1 | 6.8 Million USD | -26.1% |
| 2005 Q3 | 6.96 Million USD | -1.95% |
| 2004 Q3 | 1.02 Million USD | -22.5% |
| 2004 FY | 9.2 Million USD | 332.81% |
| 2004 Q1 | 1.61 Million USD | -23.96% |
| 2004 Q2 | 1.32 Million USD | -17.82% |
| 2004 Q4 | 9.2 Million USD | 793.72% |
| 2003 FY | 2.12 Million USD | -31.85% |
| 2003 Q4 | 2.12 Million USD | -33.55% |
| 2003 Q3 | 3.19 Million USD | 5.37% |
| 2003 Q2 | 3.03 Million USD | 15.46% |
| 2003 Q1 | 2.62 Million USD | -15.7% |
| 2002 Q4 | 3.11 Million USD | -40.32% |
| 2002 Q1 | 3.87 Million USD | -12.33% |
| 2002 Q2 | 4.73 Million USD | 21.94% |
| 2002 Q3 | 5.22 Million USD | 10.5% |
| 2002 FY | 3.11 Million USD | -29.5% |
| 2001 Q4 | 4.42 Million USD | 6.34% |
| 2001 Q1 | 3.98 Million USD | -13.45% |
| 2001 FY | 4.42 Million USD | -3.95% |
| 2001 Q2 | 3.84 Million USD | -3.45% |
| 2001 Q3 | 4.16 Million USD | 8.08% |
| 2000 Q3 | 4.26 Million USD | -23.55% |
| 2000 Q1 | 5.48 Million USD | -47.59% |
| 2000 FY | 4.6 Million USD | -55.96% |
| 2000 Q4 | 4.6 Million USD | 8.14% |
| 2000 Q2 | 5.57 Million USD | 1.66% |
| 1999 Q1 | 5.7 Million USD | -20.49% |
| 1999 Q3 | 9.31 Million USD | 79.04% |
| 1999 Q4 | 10.46 Million USD | 12.35% |
| 1999 FY | 10.46 Million USD | 45.94% |
| 1999 Q2 | 5.2 Million USD | -8.77% |
| 1998 Q2 | 9.4 Million USD | -10.48% |
| 1998 FY | 7.16 Million USD | -20.52% |
| 1998 Q4 | 7.16 Million USD | -18.54% |
| 1998 Q1 | 10.5 Million USD | 16.42% |
| 1998 Q3 | 8.8 Million USD | -6.38% |
| 1997 Q2 | 9.1 Million USD | 40.0% |
| 1997 Q3 | 9.7 Million USD | 6.59% |
| 1997 Q4 | 9.01 Million USD | -7.02% |
| 1997 Q1 | 6.5 Million USD | -24.38% |
| 1997 FY | 9.01 Million USD | 4.92% |
| 1996 Q4 | 8.59 Million USD | 86.87% |
| 1996 Q1 | 2.8 Million USD | -31.71% |
| 1996 Q2 | 3.1 Million USD | 10.71% |
| 1996 Q3 | 4.6 Million USD | 48.39% |
| 1996 FY | 8.59 Million USD | 109.66% |
| 1995 Q2 | 1.9 Million USD | -13.64% |
| 1995 Q4 | 4.1 Million USD | 28.13% |
| 1995 Q1 | 2.2 Million USD | -46.34% |
| 1995 FY | 4.1 Million USD | 0.0% |
| 1995 Q3 | 3.2 Million USD | 68.42% |
| 1994 FY | 4.1 Million USD | 127.78% |
| 1994 Q3 | 2.2 Million USD | 37.5% |
| 1994 Q4 | 4.1 Million USD | 86.36% |
| 1994 Q2 | 1.6 Million USD | -20.0% |
| 1994 Q1 | 2 Million USD | 11.11% |
| 1993 Q4 | 1.8 Million USD | 28.57% |
| 1993 FY | 1.8 Million USD | 200.0% |
| 1993 Q1 | 600 Thousand USD | 0.0% |
| 1993 Q2 | 700 Thousand USD | 16.67% |
| 1993 Q3 | 1.4 Million USD | 100.0% |
| 1992 FY | 600 Thousand USD | 0.0% |
| 1992 Q3 | 400 Thousand USD | 0.0% |
| 1992 Q4 | 600 Thousand USD | 50.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| America Great Health | 4.82 Million USD | -159.378% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -426.722% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | 67.85% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 90.564% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -350.339% |
| Better Therapeutics, Inc. | 23.84 Million USD | 47.509% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -51.073% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -25.473% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | 52.485% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | 60.624% |
| Evelo Biosciences, Inc. | 69.43 Million USD | 81.976% |
| Evolutionary Genomics, Inc. | 7.94 Million USD | -57.508% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | 73.987% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 92.045% |
| Innovation1 Biotech Inc. | 3.5 Million USD | -256.962% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | 41.216% |
| Molecular Templates, Inc. | 31.17 Million USD | 59.851% |
| NexImmune, Inc. | 5.08 Million USD | -146.152% |
| Orgenesis Inc. | 35.53 Million USD | 64.781% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | 24.207% |
| Point of Care Nano-Technology, Inc. | 266.41 Thousand USD | -4597.544% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -445.233% |
| Scopus BioPharma Inc. | 7.45 Million USD | -67.886% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 97.469% |
| Statera Biopharma, Inc. | 22.67 Million USD | 44.811% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -14.668% |
| Trevena, Inc. | 48.26 Million USD | 74.069% |
| Vaxxinity, Inc. | 30.94 Million USD | 59.556% |
| Vaccinex, Inc. | 5.94 Million USD | -110.618% |
| Vicapsys Life Sciences, Inc. | 1.96 Million USD | -535.812% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | 67.386% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -353.183% |